The Future of At-Home Diagnostics
Join JHTC at Visby Medical headquarters for an exclusive on-site tour and behind-the-scenes look at this groundbreaking healthcare company transforming at-home diagnostics.
About Visby Medical:
Visby recently achieved a major milestone with FDA De Novo authorization for the first at-home rapid Women's STI PCR test -detecting chlamydia, gonorrhea, and trichomoniasis in just 30 minutes with lab-quality accuracy.
This innovation addresses a critical health crisis: nearly 100,000 U.S. women lose fertility annually to these often-asymptomatic infections, with stigma preventing many from seeking testing.
Future products in development include male STI tests, respiratory/sore throat panels, and UTI tests with antibiotic resistance detection, all designed for home use with telemedicine support.
The Visby Difference:
Single-use device delivering PCR results in ~30 minutes at home
Rapid access via DoorDash delivery
Immediate connection to free telehealth through Optum for positive results
Available direct-to-consumer at Visby.com and through partners like Everlywell, Quest Diagnostics, and Labcorp
Meet the Founder:
Dr. Adam de la Zerda, Founder & CEO, is a tenured Stanford Medical School Associate Professor who became their youngest faculty member in 2012. A Forbes 30-under-30 honoree and TED speaker, Dr. de la Zerda brings world-class expertise in molecular diagnostics and biomedical engineering.